SCHEMBL24856050

SCHEMBL24856050

CC(NC(C)(C)C)c1ccc(N2CCN(C(=O)CCOCC(C)(C)C)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.43
▸ GAA P10253 3/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ GFER P55789 1/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ LMNA P02545 5/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ POLB P06746 1/20 0.38
▸ ME2 P23368 1/20 0.38
▸ ME1 P48163 1/20 0.38
▸ ME3 Q16798 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25133591 0.83 ALDH1A1 (0.46) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL18591772 0.81 SLC6A2 (0.40) —
SCHEMBL23664609 0.81 SMN1; SMN2 (0.45) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL18591763 0.81 MAPT (0.47) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL18530398 0.75 MAPT (0.41) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL18530448 0.75 MAPT (0.41) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL18591875 0.73 MAPT (0.49) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL20330004 0.71 SLC6A2 (0.41) GAAKDM4EALDH1A1TSHR
SCHEMBL21026182 0.70 ME2 (0.49) MAPTGAAKDM4ENPC1ALDH1A1
SCHEMBL18551120 0.70 ME2 (0.43) MAPTGAAKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL MAPT 3617/4885GAA 1531/4885KDM4E 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback